08 June 2017
: Case report
Levamisole-Induced Leukocytoclastic Vasculitis with Negative Serology in a Cocaine User
Patient complains / malpractice, Unexpected drug reaction, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Mashal Salehi1ABCDEFG*, Michael P. Morgan1ABEG, Abigail Gabriel1BDGDOI: 10.12659/AJCR.903917
Am J Case Rep 2017; 18:641-643
Abstract
BACKGROUND: Levamisole is a common adulterant of cocaine. It can cause agranulocytosis and cutaneous vasculitis that can possibly lead to cutaneous necrosis. In all reported cases of levamisole-induced vasculitis, it has been described as a clinical syndrome characterized by a constellation of typical clinical features and a positive serum serology for ANCA levels, especially very high-titer p-ANCA levels, in the background of cocaine abuse. However, patients may have a negative serology and here, we present the first such case.
CASE REPORT: A 58-year-old African American man with a history of polysubstance abuse, 4 days after last cocaine use, presented with sudden onset of painful pruritic rash and polyarthralgias. He was found to have normal vital signs, with bilateral tender knees and erythematous-purplish maculopapular lesions involving the abdomen and the left thigh. Laboratory work-up was significant for elevated CRP, negative c-ANCA, p-ANCA ANA, and RA levels, and a positive urine toxicology for cocaine. Urine analysis by high-performance liquid chromatography was positive for levamisole. Ultimately, a final diagnosis was made by skin biopsy, which revealed findings suggestive of leukocytoclastic vasculitis.
CONCLUSIONS: Cutaneous leukocytoclastic vasculitis can be caused by levamisole, which is used as an adulterant in cocaine. Most cases are associated with positive ANCA levels; however, a negative serology is also a possibility.
Keywords: Cocaine, Levamisole, Vasculitis, Leukocytoclastic, Cutaneous
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947099
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946151
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946630
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946954
Most Viewed Current Articles
21 Jun 2024 : Case report
93,594
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
51,205
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
28,023
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
22,997
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030